Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IncyteINCY -2.96%87 Cyclically Adjusted PS Ratio is 7.10 as of Aug. 01, 2026, which is 38% below its 10-year median of 11.43. GuruFocus rates INCY with a GF Score™ of 87/100 and a GF Value™ of $105.33 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 538 Biotechnology companies, Incyte ranks worse than 56.69% on this metric.
As of today (2026-08-01), Incyte's current share price is $119.52. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $16.83. Incyte's Cyclically Adjusted PS Ratio for today is 7.10.
The historical rank and industry rank for Incyte's Cyclically Adjusted PS Ratio or its related term are showing as below:
INCY'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.21 Med: 11.43 Max: 72.8
Current: 7.1
During the past years, Incyte's highest Cyclically Adjusted PS Ratio was 72.80. The lowest was 4.21. And the median was 11.43.
INCY's Cyclically Adjusted PS Ratio is ranked worse than 56.69% of 538
companies
in the Biotechnology industry
Industry Median: 5.53
vs INCY: 7.10
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Incyte's adjusted revenue per share data for the three months ended in Jun. 2026 was $8.040. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $16.83 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Incyte (NAS:INCY) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Incyte Cyclically Adjusted PS Ratio Related Terms
Incyte Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Incyte's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCY vs INSM, BNTX, ROIV: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Incyte's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 7.10 mean?
Incyte (INCY) has a Cyclically Adjusted PS Ratio of 7.10 as of Aug. 01, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors. This is 38% below median its historical median of 11.43. Over the past decade, Incyte's Cyclically Adjusted PS Ratio has ranged from 4.21 to 72.80. According to the industry distribution chart, Incyte ranks #305 out of 538 companies in the Biotechnology industry, placing it in the top 56.7%.
Is Incyte's Cyclically Adjusted PS Ratio too high?
Incyte's current Cyclically Adjusted PS Ratio of 7.10 is 38% below median its 10-year median of 11.43. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 72.80. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.53. Incyte's value of 7.10 is 28.4% above this industry median. Based on the distribution chart, Incyte ranks #305 out of 538 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Incyte has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted PS Ratio compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #305 out of 538 companies for Cyclically Adjusted PS Ratio. This places Incyte in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.53. Incyte's value of 7.10 is 28.4% above this benchmark. Historically, Incyte's own Cyclically Adjusted PS Ratio has ranged from 4.21 to 72.80 over the past decade. While the company's 10-year median is 11.43 vs. the industry median of 5.53, Incyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.53, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current Cyclically Adjusted PS Ratio of 7.10 is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Cyclically Adjusted PS Ratio is 7.10, which is 38% below median its own 10-year median of 11.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $105.33, compared to a current price of $119.52 — trading 13.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 7.10, which is 38% below median its 10-year median of 11.43 and 28.4% above the Biotechnology industry median of 5.53. Incyte's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Incyte (INCY), the current Cyclically Adjusted PS Ratio is 7.10 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of $119.52 is trading 13.5% above its estimated GF Value™ of $105.33.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for INCY:
Cyclically Adjusted PS Ratio: 7.10 (38% below median its 10-year median of 11.43)
GF Value™: $105.33 vs. price of $119.52 (13.5% above fair value)
Industry Position: 28.4% above the Biotechnology median (#305 of 538)
No single metric tells the full story. See the INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score
Get the complete analysis for INCY
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCY has been successfully added to your 
